EVENTS & PRESENTATIONS

Join us as we share our achievements and vision at global events

Upcoming Events

JPM Healthcare Conference 2025

13-16 January 2025
San Francisco, USA

34th Annual Meeting of the Society for Virology

4-7 March 2025
Hamburg, Germany

38 th International Conference on Antiviral Research (ICAR)

17-21 March 2025
Las Vegas, USA

Corporate Presentation

Presentations

Preclinical efficacy and safety of AIC468, a first-in-class antiviral antisense oligonucleotide for the treatment of BKV infection in kidney transplant recipients

April 2024. ECCMID, Barcelona

Preclinical Characterization of a Novel Anti-Viral Antisense Oligonucleotide (AIC468) in Clinical Development for Treatment of BKV Infections in Kidney Transplant Recipients

June 2024, ATC, Philadelphia

Aicuris presents novel data on its candidate AIC468, an antisense oligonucleotide for treatment of BKV infections

Our team has been making waves at the 34th ESCMID Global in Barcelona and the ATC2024 in Philadelphia with lively discussions around impressive AIC468 data at the respective poster sessions. AIC468 is a first-in-class antiviral antisense oligonucleotide in clinical development for the treatment of BKV infection in kidney transplant recipients. If you are interested to learn more about this promising program, you can download the presented posters here.

Aicuris Senior Management heading to San Francisco for the J.P. Morgan Annual Healthcare Conference from January 8th–11th

Meet with our CEO Larry Edwards and CFO Sabrina Kuttruff-Coqui at the J.P. Morgan Annual Healthcare Conference. With Senior Management from both our German headquarters and US subsidiary joining, we are looking forward to starting off the new year 2024 with an inspirational week of meetings and the opportunity to connect to stakeholders of the biotech industry. If you are interested in discussing novel antiviral therapy options for patients with a weakened immune system, as well as exciting business opportunities, ask for a meeting via info@aicuris.com.